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A B S T R A C T
Although it remained controversial for a long time, central nervous system (CNS) involvement of graft-versus-
host disease (GVHD) is now becoming recognized as a real nosological entity. Previous case reports have sug-
gested heterogeneous clinical presentations and it is not excluded that the whole spectrum of manifestations has
not yet been fully described. Here, we report the case of a 58-year-old man with chronic GVHD who developed a
rapidly ingravescent encephalopathy. There was no evidence for CNS immune-mediated lesions on conventional
imaging nor for cellular inﬁltration in the cerebrospinal ﬂuid. Serum analyses revealed the presence of anti-
neuronal antibodies directed against anti-contactin-associated protein 2 (anti-Caspr2), a protein associated with
voltage-gated potassium neuronal channels. Functional imaging with 2-deoxy-2-[ﬂuorine-18] ﬂuoro- D-glucose
integrated with computed tomography (18F-FDG PET-CT) demonstrated diﬀuse cortical and subcortical hypo-
metabolism. The patient was treated with a combination of immunosuppressive agents (corticosteroids, cyclo-
phosphamide and rituximab) and progressively recovered normal neurocognitive functions. Taken together,
these data suggest that CNS-GVHD may manifest as a reversible antibody-mediated functional encephalopathy.
This report suggests for the ﬁrst time the interest of screening for anti-neuronal antibodies and functional
imaging with brain 18F-FDG PET-CT in diagnosing this severe complication of allogeneic hematopoietic cell
transplantation (alloHSCT).
1. Introduction
Allogeneic hematopoietic stem cell transplantation (alloHSCT) oﬀers
curative treatment for a number of hematological malignancies
(Appelbaum et al., 2004, Copelan, 2006, Gratwohl et al., 2010, Majhail
et al., 2015,). However, its outcome can be compromised by the occur-
rence of graft-versus-host disease (GVHD), a complex pathologic process
in which donor immune cells attack the recipient's healthy tissues (Abou-
Mourad et al., 2010; Bhatia et al., 2007; Ferrara et al., 2009; Schmitz
et al., 2006; Solomon et al., 2017). Common targets are the skin, gastro-
intestinal tract and liver, especially in the acute form of GVHD. Progres-
sion to chronic form may theoretically aﬀect any organ and is char-
acterized by clinical manifestations resembling those observed in auto-
immune disorders (Jagasia et al., 2015, Pechey et al., 2015, Terada et al.,
2017). Few cases of GVHD of the central nervous system (CNS-GVHD)
have been reported so far (Ruggiu et al., 2017). However, it is not ex-
cluded that this complication is underdiagnosed (Armstrong et al., 1997;
Rouah et al., 1988). Here, we report the case of a 58-year-old man with
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probable CNS-GVHD manifesting as a severe neuronal surface antibody-
mediated encephalopathy.
2. Case report
The patient had a history of Philadelphia chromosome-positive B-
cell acute lymphoblastic leukemia (Phi+ B-LLA) for which he had
undergone a non-myeloablative alloHSCT with peripheral blood stem
cells from a 10/10 HLA-matched unrelated donor in January 2016.
GVHD prophylaxis consisted of tacrolimus and rapamycin (in the con-
text of a study protocol). Tacrolimus was stopped at month 6 and ra-
pamycin at month 10. The patient had also received maintenance
therapy with imatinib for Phi+ B-ALL and was in complete remission
one year after alloHSCT.
At one year after alloHSCT, he presented with oral lichen planus and
dry-eye symptoms with a pathological Schirmer test (0 and 3mm) and
signs of keratoconjunctivitis sicca on corneal ﬂuorescein staining ex-
amination. Topical therapies with dexamethasone mouthwashes and cy-
closporine eye drops were initiated. A few weeks later, he developed
pericardial eﬀusion, without evidence of parainfectious or paraneoplastic
etiology. Simultaneously, he started complaining of progressive asthenia,
drowsiness, inattention, irritability, moderate transient headaches and
weight loss. The clinical examination revealed bradypsychia, cognitive
impairment, dyspraxia, ataxia, a pyramidal syndrome, and autonomic
dysfunction with orthostatic hypotension and hyperhidrosis.
The electroencephalogram (EEG) showed diﬀuse moderate slowing
of the dominant rhythm without paroxysmal activity. Screening tests
for common metabolic or toxic causes of encephalopathy were nega-
tive. The brain magnetic resonance imaging (MRI) demonstrated only
mild non-speciﬁc infra- and supratentorial leukoencephalopathy, that
was stable in comparison with an MRI performed 1 year before. A
lumbar puncture was performed and the cerebrospinal ﬂuid (CSF)
analyses revealed 5 leucocytes/μL, normal glycorrachia but hyperpro-
teinorachia (936mg/L) with elevated immunoglobulin G (IgG, 66mg/
L) with an oligoclonal proﬁle (isoelectric focusing). Reiber's graph did
not suggest active intrathecal IgG secretion but rather an abnormal
blood-brain barrier (BBB) permeation (IgG index of 6.8). Direct ex-
amination and microbiological cultures of the CSF were negative.
Cryptococcal antigen was not detected and the panel PCR assay (in-
cluding PCR for HSV-1 and -2, EBV, CMV, VZV, HHV6, enterovirus,
parechovirus, BK/JC virus, toxoplasma and Listeria monocytogenes) re-
turned negative. There was no evidence of leukemic cerebro-meningeal
inﬁltration on cytology, immunophenotyping and molecular analyses.
Serum analyses revealed a non-speciﬁc activation of the humoral im-
munity with an elevated titer of homogeneous antinuclear antibodies
(dilution: 1/2560) with anti-nucleosome characterization (52 U/mL).
Anti-neuronal antibodies were screened in the serum and antibodies
directed against contactin associated protein like 2 (Caspr2, a protein
associated with voltage-gated potassium neuronal channels) were
found (immunoﬂuorescent assay on transfected cells) (Fig. A1). A chest
CT scan was performed and excluded a thymoma or a lung cancer.
Rapidly (within 10–14 days), neurological symptoms worsened, with
progressive confusion, mutism, dizziness and ﬂuctuations of consciousness.
A 18F-FDG brain PET-CT demonstrated diﬀuse cortical and subcortical
hypometabolism. Fifteen days after his admission, the patient presented a
generalized epileptic seizure, followed by a profound alteration of con-
sciousness (without argument for status epilepticus) and was transferred to
the intensive care unit. A control brain MRI did not reveal any novel phe-
nomenon. A second lumbar puncture was superimposable to the ﬁrst one.
Based on the lack of evidence for any other cause, the context of oral
and ocular cGVHD, seritis and biological signs of dysimmunity as well
as the recent discontinuation of immunosuppressive drugs, we con-
sidered that the diagnosis of CNS-GVHD was probable and treatment
with high dose corticosteroids was initiated (IV methylprednisolone
1 g/day for 5 days, standard to protocols for CNS autoimmune en-
cephalitis), in addition to supportive care and antiepileptic therapy
with levetiracetam. The patient rapidly recovered consciousness and
returned back to the conventional care unit. We decided to continue
maintenance therapy with 1mg/kg/day oral methylprednisolone in
combination with IV boluses of cyclophosphamide (Cy, 500mg/m2
every 3 weeks). Given the biological signs of humoral immunity acti-
vation with anti-neuronal antibodies, we added rituximab (375mg/m2
once a week, for 4 administrations).
Neurocognitive functions recovered progressively over a few
months. No epileptic seizure recurred. The treatment also enabled im-
provement of GVHD mouth and ocular symptoms as well as complete
regression of the pericardial eﬀusion. At six months, control EEG and
brain PET-CT showed normalization of the cerebral electrical activity
and cortical metabolism, respectively. From that moment on, the pa-
tient had recovered completely normal neurocognitive functions. At
month 10, anti-Caspr2 antibodies were negative. Considering this fa-
vorable evolution, dosage of corticosteroids was gradually tapered after
three months of their introduction (approximately 20% of dose reduc-
tion every 1–2weeks during two months) to reach a dose of 8mg/day
at 5months. This dose was maintained over 5 additional months, and
corticosteroid therapy was deﬁnitively stopped by 10months after its
initiation. Cy was maintained up to 13months, when it was dis-
continued. The patient did not experience any recurrence of abnormal
neurological signs. Periodical brain PET-CT and anti-neuronal antibody
screening are planned for the patient's follow-up in the coming years.
3. Discussion
Historically, it was considered that the CNS could not be aﬀected by
GVHD. However, over the last decade, preclinical data (Belle et al.,
2017; Hartrampf et al., 2013; Sostak et al., 2004) and clinical case re-
ports (Harvey et al., 2014; Openshaw et al., 1995; Sostak et al., 2010;
Stefanou and Bischof, 2017; Voss and Bischof, 2010) progressively ac-
cumulated and CNS-GVHD is now becoming recognized as a true entity
(Armstrong et al., 1997; Belle et al., 2017; Grauer et al., 2010;
Hartrampf et al., 2013; Harvey et al., 2014; Maﬃni et al., 2017;
Openshaw et al., 1995; Rouah et al., 1988; Ruggiu et al., 2017; Sostak
et al., 2004; Sostak et al., 2010; Stefanou and Bischof, 2017; Voss and
Bischof, 2010). Nevertheless, the diagnosis of CNS-GVHD still remains
diﬃcult mainly because of the low prevalence of the disease, con-
founding factors and heterogeneous clinical presentations. Moreover,
the whole clinical spectrum of the entity has not yet been fully de-
scribed. Previous reports have suggested that CNS-GVHD can present
with three main clinico-pathological manifestations: immune-mediated
vasculitis, immune-mediated demyelinating lesions and immune-
mediated encephalitis (Campbell and Morris, 2005; Delios et al., 2012;
Grauer et al., 2010; Harvey et al., 2014; Maﬃni et al., 2017; Padovan
et al., 1999; Ruggiu et al., 2017; Saad et al., 2009; Tomonari et al.,
2003). Here, we report a case of CNS-GVHD presenting as an in-
gravescent encephalopathy, without any signiﬁcant lesion on MRI but
with diﬀuse alteration of brain activity on 18F-FDG PET-CT imaging.
Serum analyses revealed the presence of anti-neuronal antibodies di-
rected towards a protein associated with voltage-gated potassium
neuronal channels. Neurocognitive functions completely recovered and
18F-FDG PET-CT imaging normalized after immunosuppressive
therapy. Taken together, these data suggest that CNS-GVHD could also
manifest as a reversible immune-mediated encephalopathy.
In 2009, Openshaw described six diagnostic criteria for CNS-GVHD,
including: (1) chronic GVHD aﬀecting other organs, (2) neurological
signs of CNS involvement without other explanation, (3) abnormal CSF
studies (pleocytosis, elevated protein or immunoglobulin G, oligoclonal
bands), (4) brain MRI abnormality, (5) pathological brain biopsy or
post-mortem examination and (6) response to immunosuppressive
therapy (Openshaw, 2009). Initially, all of those six criteria were con-
sidered mandatory to make the deﬁnite diagnosis of CNS-GVHD.
However, in a report from the Consensus Conference on Clinical Prac-
tice in chronic graft-versus-host disease (Grauer et al., 2010), Grauer
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et al. proposed more ﬂexibility and suggested that the diagnosis of
‘possible’ CNS-GVHD could also be made when the ﬁrst two criteria and
at least two of the 4 remaining criteria were met, considering that pa-
thological ﬁndings on brain MRI, CSF studies or brain histology could
be facultative, as well as response to treatment (Grauer et al., 2010). In
our case, four criteria were met. Interestingly, brain MRI did not reveal
any signiﬁcant parenchymal lesions. We did not attempt to perform a
brain biopsy, both because of the lack of speciﬁc MRI abnormalities for
guiding relevant biopsy and because of rapid clinical deterioration
prompting initiation of empirical immunosuppressive therapy.
In our case, 18F-FDG brain PET-CT demonstrated diﬀuse cortical
and subcortical hypometabolism that completely normalized following
immunosuppressive therapy. Functional imaging with 18F-FDG brain
PET-CT recently emerged as a useful tool for improving the diagnosis of
some auto-immune encephalitis (Celliers et al., 2016; Dong et al., 2016;
Lagarde and Guedj, 2015; Morbelli et al., 2017). Whether it could also
bring relevant complementary information to integrate in the diag-
nostic algorithm of CNS-GVHD, especially in patients with normal MRI,
is not known and has to be explored in the future.
Serum analyses from our patient revealed the presence of anti-
neuronal antibodies directed against Caspr2, a protein associated with
voltage-gated potassium neurological channels. The clinical spectrum
of anti-Caspr2 antibody-associated autoimmune disease is still not well
established. Most patients have symptoms originating from multiple
areas of the nervous system (e.g. limbic encephalitis, Morvan's syn-
drome, neuromyotonia …). By studying one of the largest series of 38
patients with anti-Caspr2 auto-antibodies, Van Sonderen et al. recently
reported that the resulting syndrome might indeed be diverse, including
a set of symptoms such as cognitive deﬁcits, epilepsy, insomnia, cere-
bellar dysfunction, autonomic dysfunction, peripheral nerve hyper-
excitability, neuropathic pain, and weight loss (Van Sonderen et al.,
2016). Our patient presented with several of these symptoms.
The Reiber's graph on CSF was not evocative of an active intrathecal
secretion of IgG, but rather suggested a passive transfer of peripheral
antibodies through the inﬂamed BBB. Search for antineuronal antibody
in the serum and in the CSF is theoretically the best approach for di-
agnosing encephalitis (Grauss et al., 2016). Unfortunately, anti-Caspr2
antibodies were not screened in the CSF of our patient because of
practical limitation in our institution. However, the detection of anti-
Caspr2 antibodies in the serum, the compatible clinical presentation,
the abnormal neuronal activity on brain PET-CT as well as the rapid
clinical improvement under immunosuppressive therapy support the
diagnosis of immune-mediated encephalopathy in our patient. Asso-
ciation between anti-Caspr2 antibodies and solid malignancies have
been reported in some cases (Popławska-Domaszewicz et al., 2018).
Here, the presence of other signs of cGVHD, the normal chest CT-scan
and the favorable clinical evolution (good general well-being at more
than one year of follow-up) can reasonably rule out the hypothesis of a
paraneoplastic syndrome in our patient.
To the best of our knowledge, this is the ﬁrst case report of CNS-GVHD
with evidence of humoral dysimmunity. Previous clinical reports mainly
mentioned T-cell mediated CNS lesions or encephalitis (Iwasaki et al.,
1993; Kamble et al., 2007; Marosi et al., 1990; Saad et al., 2009). How-
ever, it is now recognized that B cells play an important role in the pa-
thophysiology of systemic chronic GVHD (MacDonald et al., 2017;
Rhoades and Gaballa, 2017). Considering biological signs of B-cell acti-
vation in our patient, we added anti-B cell treatment with rituximab (an
anti-CD20 antibody) to corticosteroid-cyclophosphamide combination
therapy. Eﬃcacy of rituximab for the treatment of chronic GVHD has been
proven in several studies (Brownback et al., 2017; Wolﬀ et al., 2011).
The patient progressively recovered normal neurocognitive functions
and PET-CT imaging normalized under immunosuppressive therapy, sug-
gesting the reversible course of the disease under treatment.
4. Conclusion
CNS-GVHD should be included in the diﬀerential diagnosis of en-
cephalopathy in patients after alloHSCT, particularly if they present
signs of GVHD in other organs. A rapid work-up is essential to promptly
initiate appropriate immunosuppressive treatment. Screening for anti-
neuronal antibodies and the use of functional imaging with brain 18F-
FDG PET-CT should be considered as additional tools to help the di-
agnosis. In such diﬃcult cases, close collaboration between neurologists
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